Epithra 50 Injection contains Epirubicin 50 mg, an anthracycline antibiotic used as a chemotherapeutic agent in the treatment of various malignancies. Epirubicin exerts its antineoplastic effects primarily by intercalating DNA strands, thereby inhibiting topoisomerase II activity, which leads to disruption of DNA replication and transcription, ultimately inducing apoptosis in rapidly dividing cancer cells. This medication is commonly indicated for breast cancer, ovarian cancer, lung cancer, gastric cancer, and bladder cancer, among others. Epithra 50 Injection is administered intravenously under strict medical supervision, with dosage and treatment schedules tailored according to the specific cancer type, stage, and patient tolerance. Due to its potential cardiotoxicity, baseline and periodic cardiac function assessments are essential during therapy. Common adverse effects include myelosuppression, nausea, vomiting, alopecia, mucositis, and potential extravasation reactions at the injection site. Caution is advised in patients with pre-existing cardiac conditions, hepatic impairment, or bone marrow suppression. Epithra 50 Injection should not be used in pregnant or breastfeeding women unless the potential benefits outweigh the risks. Proper handling and administration protocols must be followed to minimize exposure risks to healthcare personnel. This medication requires careful monitoring to optimize therapeutic outcomes while minimizing toxicity.